$7.84
$-5.76 (-35.10%)
End-of-day quote: 07/21/2022
NasdaqGS:CDXS

Codexis (CDXS)

Codexis, Inc. discovers, develops, and sells enzymes and other proteins.

If you are interested in CDXS stock information, you might also be interested in competitors like LSE:JMAT.

With a P/E ratio of 0.00, the stock appears relatively cheap compared to its index ^SPX at the moment.

The market capitalization of Codexis is currently at $0.57 B. This places it among the low capitalized companies.

The book value reported in the balance sheet results in a P/B ratio of 3.23.

With one share of Codexis investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.

For the risk analysis, the high beta factor should be noted, which is currently at a value of 1.60. The price of the stock NasdaqGS:CDXS is therefore subject to relatively strong fluctuations in relation to the overall market.

7.52% of CDXS Stocks is owned by insiders.

For Wall Street analysts, a price target of $22.25 is currently considered realistic.

NasdaqGS:CDXS has a 52 week range of $6.15 - $42.01 and is currently trading around $7.84.

The low short sale ratio indicated that the value might increase in the foreseeable future.

0
Underperform
1
2
3
4
5
6
7
8
9
10
1M 3M YTD 1Y 2Y 5Y 10Y 20Y
P/E Ratio
0.0
Market Cap
0.57B
LT Debt/Cap
0.02%
Price-to-book Ratio
3.23
Earnings
11/04/2022
Dividend
$0.00
Div Yld
0.00%
Dividend Growth
0 Years
Beta
1.60
Short Interest
8.47%
Forecast 1Y
0.00%
Analyst Price Target
$22.25
LTG 5Y
0.00%
52 week range
$6.15 - $42.01